QIP Approved
The company approved the initiation of a qualified institutional placement of equity shares, each with a nominal value of ₹1, aimed at raising capital from qualified institutional buyers.
The board has approved the preliminary placement document, permitted the commencement of the issue in accordance with SEBI ICDR regulations and the Companies Act, and established a regulatory-compliant floor price of ₹372.57 per share, with the option to provide a discount of up to 5%.
The company has submitted the preliminary placement document to the exchanges and has announced that its trading window will be closed for designated individuals from 25 August 2026 until 48 hours after the issue price is finalised.
This QIP initiative highlights the company’s strategy to access institutional capital markets, which may bolster its balance sheet and improve financial flexibility, while also indicating a greater commitment to regulatory-compliant fundraising methods.
Q1 Results
In the first quarter of FY27, Gujarat Themis Biosyn achieved operational income of ₹43.79 crore, an increase from ₹35.87 crore in the first quarter of FY26. The company experienced a 22% year-on-year rise in standalone net profit, reaching ₹11.07 crore for the June quarter.
Profitability also saw improvement at the operational level. The Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for Q1 FY27 was reported at ₹20.79 crore, with the EBITDA margin increasing to 47.5% from 38.8% in the previous year. The profit before tax (PBT) for the quarter stood at ₹15.17 crore.
Additionally, the company reported an earnings per share (EPS) of ₹1.02 for Q1 FY27, compared to ₹0.83 in Q1 FY26.
Stock Performance
The shares of Gujarat Themis Biosyn are trading higher, having surged over 5% intraday.
The rise has eased slightly, to over 4%. The shares have seen a rise of over 36% in the past 6 months. The share price is now at ₹424.55 per share.
(Edited by : Gareema Bangad)
First Published: Aug 26, 2026 10:44 AM IST
